| Literature DB >> 30082920 |
Rubén Cebrián1,2, Sergio Arévalo1, Susana Rubiño1, Salvador Arias-Santiago3, María Dolores Rojo4, Manuel Montalbán-López1, Manuel Martínez-Bueno1, Eva Valdivia1, Mercedes Maqueda5.
Abstract
We report the high susceptibility of several clinical isolates of Propionibacterium acnes from different sources (skin, bone, wound exudates, abscess or blood contamination) to the head-to-tail cyclized bacteriocin AS-48. This peptide is a feasible candidate for further pharmacological development against this bacterium, due to its physicochemical and biological characteristics, even when it is growing in a biofilm. Thus, the treatment of pre-formed biofilms with AS-48 resulted in a dose- and time-dependent disruption of the biofilm architecture beside the decrease of bacterial viability. Furthermore, we demonstrated the potential of lysozyme to bolster the inhibitory activity of AS-48 against P. acnes, rendering high reductions in the MIC values, even in matrix-growing cultures, according to the results obtained using a range of microscopy and bioassay techniques. The improvement of the activity of AS-48 through its co-formulation with lysozyme may be considered an alternative in the control of P. acnes, especially after proving the absence of cytotoxicity demonstrated by these natural compounds on relevant human skin cell lines. In summary, this study supports that compositions comprising the bacteriocin AS-48 plus lysozyme must be considered as promising candidates for topical applications with medical and pharmaceutical purposes against dermatological diseases such as acne vulgaris.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30082920 PMCID: PMC6079106 DOI: 10.1038/s41598-018-29580-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Minimal inhibitory concentration of AS-48 alone and in combination with lysozyme assayed by the microdilution method.
| Isolate | AS-48 (µg/mL) | AS-48 (µg/mL) + Lysozyme (0.40 mg/mL) | Isolate | AS-48 (µg/mL) | AS-48 (µg/mL) + Lysozyme (0.40 mg/mL) |
|---|---|---|---|---|---|
|
|
| ||||
| P0 | 0.62 | 0.052** | P6 | 1.25 | 0.86/0.15 |
| P3 | 1.25 | 0.26 | P7 | 2.50 | — |
| P4 | 0.62 | — | P15 | 0.94 | 0.625 |
| P11 | 0.62 | 0.47 | P17 | 1.25 | 0.104** |
| P12 | 0.75 | 0.019** | P18 | 1.25 | 0.93 |
| P13 | 0.94 | 0.39 | P19 | 2.50 | 0.62 |
| P24 | 1.87 | 1.87 | P20 | 1.25 | 0.62 |
|
| P22 | 0.62 | 0.019** | ||
| P1 | 0.94 | 0.286 | P26 | 1.25 | 0.62 |
| P10 | 1.87 | 0.62 | P27 | 0.92 | 0.065** |
| P25 | 1.25 | 0.62 | |||
Non-cooperative effect is shown underlined. **Represents the most significant MIC reductions (more than 10x). The results are representative of three or more independent experiments.
Figure 1Scanning electron micrographs of the P27 cells growing in a biofilm. (A) Massive numbers of bacilli partially occluded by dehydrated material (untreated control) and progressive reduction of cell proliferation by the addition of 0.10, 1.00 and 10.00 µg/mL of AS-48 at T0. (B) Morphology of the P27 cells added of different AS-48 concentrations at T0. (C) Membrane-surface retraction on cells treated with high concentrations of AS-48.
Figure 2Transmission electron micrographs (TEM) of the P27 cells growing alone (A) and in the presence of 0.10 (B), 1.00 (C) and 10.00 µg/mL (D) of AS-48 at T0. The arrows shown the membrane-surface retraction on cells treated with high concentrations of AS-48.
Figure 3Effect of AS-48 on P27 cells growing in a biofilm visualized by SEM at increasing magnifications at T24. (A) Bacilli are embedded in fimbriae-like structures (control). (B) Networks of fibrils surrounding and entangling the bacilli after AS-48 addition (1.00 µg/mL). (C) Details of the networks with a progressive higher magnification.
Figure 4Flow cytometry analysis of P. acnes P0 strain growing in biofilms and exposed to several concentrations of AS-48 and AS-48 plus lysozyme, stained with acridine orange and propidium iodide[41]. Percentage of dead cells after the tratments, according to the flow cytometry analysis in relation to control of death (80 °C, 20 min). *Significant differences according to Anova one-way Posthoc LSD (p < 0.05).
Figure 5Killing kinetics of AS-48. Growth of P. acnes (log CFU/mL) after prolongued exposure to different AS-48 concentrations (A) or a combination of AS-48 with 4.00 mg/mL lysozyme (B). A control with no antimicrobial (dark blue) was used.
Figure 6Viability of the A2058 and CCD25sk cell lines (% in relation to control) after the treatment with several concentrations of AS-48 alone or in presence of lysozyme (4.00 mg/mL). Lysoz: control of lysozyme. Control: untreated cells.